AACR and MPM Oncology Charitable Foundation Announce Three Grants to Support Transformative Cancer Research pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones
Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today provided a review of corporate highlights from 2020 and outlined anticipated key clinical program milestones for 2021. While 2020 was marked by tremendous challenges due to the COVID-19 pandemic, Forma made important strides due to the courage of patients and the dedication of our employees. We reported promising results our from our clinical programs including FT-4202 in sickle cell disease, olutasidenib in both AML and glioma, and FT-7051 in prostate cancer, and also raised approximately $695 million in public equity offerings, said Frank Lee, president and chief executive officer of Forma. In this coming year, we anticipate continued progress, and look forward to advancing drug
from the magazine
Patient, Heal Thyself Treatments from our own cells could cure many diseases if Washington will only allow it to happen.
Health Care
Personalized medicine” has become a familiar term that refers to the process of fitting drugs to patient molecular profiles that make it likely that the drugs will perform effectively and safely. Now emerging is literally personal medicine: treatments derived entirely from a patient’s own cells, or almost so, and largely controlled by the nimble and powerful biochemical know-how already embedded in those cells.
Unlike conventional drugs, these cell therapies are created from scratch, one patient at a time, and many of the tools used to create them are simple, compact, and cheap enough to land in laboratories that serve hospitals, small clinics, and doctors in private practice. They have been landing there in growing numbers in the last decade, and Washington has been trying to keep pace. The Food and Drug Admi
Harpoon Therapeutics : Clin Cancer Res 2021; OnlineFirst version Jan 6, 2021 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Wistar scientists characterized an inhibitor that targets acetate metabolism in cancer cells. This molecule caused tumor growth inhibition and regression in preclinical studies, demonstrating the promise of this approach as. view more
Credit: The Wistar Institute
PHILADELPHIA (Jan. 7, 2021) Scientists at The Wistar Institute characterized an inhibitor that targets acetate metabolism in cancer cells. Cancer cells use acetate metabolism to support tumor growth in conditions of low nutrient and oxygen availability. This molecule caused tumor growth inhibition and regression in preclinical studies, demonstrating the promise of this approach as a novel therapeutic strategy for solid tumors. Study results were published today in